Theracryf Management
Management criteria checks 4/4
Theracryf's CEO is Huw Jones, appointed in Oct 2020, has a tenure of 4.08 years. total yearly compensation is £302.89K, comprised of 71% salary and 29% bonuses, including company stock and options. directly owns 0.75% of the company’s shares, worth £19.11K. The average tenure of the management team and the board of directors is 3.5 years and 9.1 years respectively.
Key information
Huw Jones
Chief executive officer
UK£302.9k
Total compensation
| CEO salary percentage | 71.0% |
| CEO tenure | 4.1yrs |
| CEO ownership | 0.7% |
| Management average tenure | 3.5yrs |
| Board average tenure | 9.1yrs |
Recent management updates
Recent updates
Here's Why We're Not Too Worried About Evgen Pharma's (LON:EVG) Cash Burn Situation
Oct 11
We're Hopeful That Evgen Pharma (LON:EVG) Will Use Its Cash Wisely
Nov 24Here's Why We're Not Too Worried About Evgen Pharma's (LON:EVG) Cash Burn Situation
Aug 06Is Evgen Pharma (LON:EVG) In A Good Position To Deliver On Growth Plans?
Apr 09We're Keeping An Eye On Evgen Pharma's (LON:EVG) Cash Burn Rate
Dec 25CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | UK£303k | UK£215k | -UK£3m |
| Dec 31 2023 | n/a | n/a | -UK£3m |
| Sep 30 2023 | n/a | n/a | -UK£3m |
| Jun 30 2023 | n/a | n/a | -UK£4m |
| Mar 31 2023 | UK£305k | UK£200k | -UK£4m |
| Dec 31 2022 | n/a | n/a | -UK£4m |
| Sep 30 2022 | n/a | n/a | -UK£3m |
| Jun 30 2022 | n/a | n/a | -UK£3m |
| Mar 31 2022 | UK£240k | UK£188k | -UK£3m |
| Dec 31 2021 | n/a | n/a | -UK£3m |
| Sep 30 2021 | n/a | n/a | -UK£2m |
| Jun 30 2021 | n/a | n/a | -UK£3m |
| Mar 31 2021 | UK£224k | UK£88k | -UK£3m |
Compensation vs Market: Huw's total compensation ($USD392.34K) is about average for companies of similar size in the UK market ($USD369.71K).
Compensation vs Earnings: Huw's compensation has been consistent with company performance over the past year.
CEO
Huw Jones (65 yo)
4.1yrs
Tenure
UK£302,890
Compensation
Dr. Huw Jones, BSc, Ph D., serves as Non-Executive Director of Ixaka Limited since August 2023. He serves as Chief Executive Officer at Theracryf Plc (formerly known as Evgen Pharma plc) since October 1, 2...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 4.1yrs | UK£302.89k | 0.75% £ 19.1k | |
| CFO & Director | 1.2yrs | UK£385.25k | 0.23% £ 6.0k | |
| Chief Business Officer | 3.6yrs | no data | 0.25% £ 6.3k | |
| Chief Medical Officer | 3.5yrs | no data | 0.23% £ 6.0k |
3.5yrs
Average Tenure
Experienced Management: TCF's management team is considered experienced (3.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | no data | UK£302.89k | 0.75% £ 19.1k | |
| CFO & Director | less than a year | UK£385.25k | 0.23% £ 6.0k | |
| Chair & Senior Independent Director | 10yrs | UK£36.39k | 0.17% £ 4.4k | |
| Independent Non-Executive Director | 9.1yrs | UK£22.91k | no data |
9.1yrs
Average Tenure
66yo
Average Age
Experienced Board: TCF's board of directors are considered experienced (9.1 years average tenure).